Skip to main content
Erschienen in: Diabetologia 5/2009

01.05.2009 | Article

Circadian rhythms of GIP and GLP1 in glucose-tolerant and in type 2 diabetic patients after biliopancreatic diversion

verfasst von: G. Mingrone, G. Nolfe, G. Castagneto Gissey, A. Iaconelli, L. Leccesi, C. Guidone, G. Nanni, J. J. Holst

Erschienen in: Diabetologia | Ausgabe 5/2009

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

We tested the hypothesis that the reversibility of insulin resistance and diabetes observed after biliopancreatic diversion (BPD) is related to changes in circadian rhythms of gastrointestinal hormones.

Methods

Ten morbidly obese participants, five with normal glucose tolerance (NGT) and five with type 2 diabetes, were studied before and within 2 weeks after BPD. Within-day variations in glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP1) levels were assessed using a single cosinor model. Insulin sensitivity was assessed by euglycaemic–hyperinsulinaemic clamp.

Results

Basal GLP1 relative amplitude (amplitude/mesor × 100) was 25.82–4.06% in NGT; it increased to 41.38–4.32% after BPD but was unchanged in diabetic patients. GLP1 and GIP mesor were shifted in time after surgery in diabetic patients but not in NGT participants. After BPD, the GLP1 AUC significantly increased from 775 ± 94 to 846 ± 161 pmol l−1 min in NGT, whereas GIP AUC decreased significantly from 1,373 ± 565 to 513 ± 186 pmol l−1 min in diabetic patients. Two-way ANOVA showed a strong influence of BPD on both GIP (p = 0.010) and GLP1 AUCs (p = 0.033), which was potentiated by the presence of diabetes, particularly for GIP (BPD × diabetes, p = 0.003). Insulin sensitivity was markedly improved (p < 0.01) in NGT (from 9.14 ± 3.63 to 36.04 ± 8.55 µmol [kg fat-free mass]−1 min−1) and diabetic patients (from 9.49 ± 3.56 to 38.57 ± 4.62 µmol [kg fat-free mass]−1 min−1).

Conclusions/interpretation

An incretin circadian rhythm was shown for the first time in morbid obesity. The effect of BPD on the 24 h pattern of incretin differed between NGT and diabetic patients. GLP1 secretion impairment was reversed in NGT and could not be overcome by surgery in diabetes. On the other hand, GIP secretion was blunted after the operation only in diabetic patients, suggesting a role in insulin resistance and diabetes.
Literatur
1.
Zurück zum Zitat Vilsbøll T, Holst JJ (2004) Incretins, insulin secretion and type 2 diabetes mellitus. Diabetologia 47:357–366PubMedCrossRef Vilsbøll T, Holst JJ (2004) Incretins, insulin secretion and type 2 diabetes mellitus. Diabetologia 47:357–366PubMedCrossRef
2.
Zurück zum Zitat Nauck M, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W (1993) Preserved incretin activity of glucagon-like peptide 1 [7–36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91:301–307PubMedCrossRef Nauck M, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W (1993) Preserved incretin activity of glucagon-like peptide 1 [7–36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91:301–307PubMedCrossRef
3.
Zurück zum Zitat Nauck M, Stöckmann F, Ebert R, Creutzfeldt W (1986) Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29:46–52PubMedCrossRef Nauck M, Stöckmann F, Ebert R, Creutzfeldt W (1986) Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29:46–52PubMedCrossRef
4.
Zurück zum Zitat Zimmet P, Alberti KG, Shaw J (2001) Global and societal implications of the diabetes epidemic. Nature 414:782–787PubMedCrossRef Zimmet P, Alberti KG, Shaw J (2001) Global and societal implications of the diabetes epidemic. Nature 414:782–787PubMedCrossRef
5.
Zurück zum Zitat Leibson CL, Williamson DF, Melton LJ 3rd et al (2001) Temporal trends in BMI among adults with diabetes. Diabetes Care 24:1584–1589PubMedCrossRef Leibson CL, Williamson DF, Melton LJ 3rd et al (2001) Temporal trends in BMI among adults with diabetes. Diabetes Care 24:1584–1589PubMedCrossRef
6.
Zurück zum Zitat Golay A, Ybarra J (2005) Link between obesity and type 2 diabetes. Best Pract Res Clin Endocrinol Metab 19:649–663PubMedCrossRef Golay A, Ybarra J (2005) Link between obesity and type 2 diabetes. Best Pract Res Clin Endocrinol Metab 19:649–663PubMedCrossRef
7.
Zurück zum Zitat Muscelli E, Mari A, Casolaro A et al (2008) Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes 57:1340–1348PubMedCrossRef Muscelli E, Mari A, Casolaro A et al (2008) Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes 57:1340–1348PubMedCrossRef
8.
Zurück zum Zitat Anderson JW, Grant L, Gotthelf L, Stifler LT (2006) Weight loss and long-term follow-up of severely obese individuals treated with an intense behavioral program. Int J Obes 31:488–493CrossRef Anderson JW, Grant L, Gotthelf L, Stifler LT (2006) Weight loss and long-term follow-up of severely obese individuals treated with an intense behavioral program. Int J Obes 31:488–493CrossRef
9.
Zurück zum Zitat MacDonald KG, Long SD, Swanson MS et al (1997) The gastric bypass operation reduces the progression and mortality of NIDDM. J Gastrointest Surg 1:213–220PubMedCrossRef MacDonald KG, Long SD, Swanson MS et al (1997) The gastric bypass operation reduces the progression and mortality of NIDDM. J Gastrointest Surg 1:213–220PubMedCrossRef
10.
Zurück zum Zitat Rubino F, Gagner M, Gentileschi P et al (2004) The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg 240:236–242PubMedCrossRef Rubino F, Gagner M, Gentileschi P et al (2004) The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg 240:236–242PubMedCrossRef
11.
Zurück zum Zitat Guidone C, Manco M, Valera-Mora E et al (2006) Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery. Diabetes 55:2025–2031PubMedCrossRef Guidone C, Manco M, Valera-Mora E et al (2006) Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery. Diabetes 55:2025–2031PubMedCrossRef
12.
Zurück zum Zitat Laferrère B, Teixeira J, McGinty J et al (2008) Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab 93:2479–2485PubMedCrossRef Laferrère B, Teixeira J, McGinty J et al (2008) Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab 93:2479–2485PubMedCrossRef
13.
Zurück zum Zitat Laferrère B, Heshka S, Wang K et al (2007) Incretin levels and effect are markedly enhanced 1 month after roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care 30:1709–1716PubMedCrossRef Laferrère B, Heshka S, Wang K et al (2007) Incretin levels and effect are markedly enhanced 1 month after roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care 30:1709–1716PubMedCrossRef
14.
Zurück zum Zitat Rodieux F, Giusti V, D’Alessio DA, Suter M, Tappy L (2008) Effects of gastric bypass and gastric banding on glucose kinetics and gut hormone release. Obesity 16:298–305PubMedCrossRef Rodieux F, Giusti V, D’Alessio DA, Suter M, Tappy L (2008) Effects of gastric bypass and gastric banding on glucose kinetics and gut hormone release. Obesity 16:298–305PubMedCrossRef
15.
Zurück zum Zitat Pories WJ, Albrecht RJ (2001) Etiology of type II diabetes mellitus: role of the foregut. World J Surg 25:527–531PubMedCrossRef Pories WJ, Albrecht RJ (2001) Etiology of type II diabetes mellitus: role of the foregut. World J Surg 25:527–531PubMedCrossRef
16.
Zurück zum Zitat Mingrone G, DeGaetano A, Greco AV et al (1997) Reversibility of insulin resistance in obese diabetic patients: role of plasma lipids. Diabetologia 40:599–605PubMedCrossRef Mingrone G, DeGaetano A, Greco AV et al (1997) Reversibility of insulin resistance in obese diabetic patients: role of plasma lipids. Diabetologia 40:599–605PubMedCrossRef
17.
Zurück zum Zitat Camastra S, Manco M, Mari A et al (2007) Beta-cell function in severely obese type 2 diabetic patients: long-term effects of bariatric surgery. Diabetes Care 30:1002–1004PubMedCrossRef Camastra S, Manco M, Mari A et al (2007) Beta-cell function in severely obese type 2 diabetic patients: long-term effects of bariatric surgery. Diabetes Care 30:1002–1004PubMedCrossRef
18.
Zurück zum Zitat Mari A, Manco M, Guidone C et al (2006) Restoration of normal glucose tolerance in severely obese patients after bilio-pancreatic diversion: role of insulin sensitivity and beta cell function. Diabetologia 49:2136–2143PubMedCrossRef Mari A, Manco M, Guidone C et al (2006) Restoration of normal glucose tolerance in severely obese patients after bilio-pancreatic diversion: role of insulin sensitivity and beta cell function. Diabetologia 49:2136–2143PubMedCrossRef
19.
Zurück zum Zitat DeFronzo RA, Tobin JD, Andres R (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:E214–E223PubMed DeFronzo RA, Tobin JD, Andres R (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:E214–E223PubMed
20.
Zurück zum Zitat Krarup T, Madsbad S, Moody AJ et al (1983) Diminished gastric inhibitory polypeptide (GIP) response to a meal in newly diagnosed type I (insulin dependent) diabetics. J Clin Endocrinol Metab 56:1306–1312PubMedCrossRef Krarup T, Madsbad S, Moody AJ et al (1983) Diminished gastric inhibitory polypeptide (GIP) response to a meal in newly diagnosed type I (insulin dependent) diabetics. J Clin Endocrinol Metab 56:1306–1312PubMedCrossRef
21.
Zurück zum Zitat Ørskov C, Rabenhøj L, Kofod H, Wettergren A, Holst JJ (1994) Production and secretion of amidated and glycine-extended glucagon-like peptide-1 (GLP-1) in man. Diabetes 43:535–539PubMedCrossRef Ørskov C, Rabenhøj L, Kofod H, Wettergren A, Holst JJ (1994) Production and secretion of amidated and glycine-extended glucagon-like peptide-1 (GLP-1) in man. Diabetes 43:535–539PubMedCrossRef
22.
Zurück zum Zitat Simon C, Brandenberger G (2002) Ultradian oscillations of insulin secretion in humans. Diabetes 51:S258–S261PubMedCrossRef Simon C, Brandenberger G (2002) Ultradian oscillations of insulin secretion in humans. Diabetes 51:S258–S261PubMedCrossRef
23.
Zurück zum Zitat Flatt PR, Bailey CJ, Kwasowski P, Page T, Marks V (1984) Plasma immunoreactive gastric inhibitory polypeptide in obese hyperglycaemic (ob/ob) mice. J Endocrinol 101:249–256PubMedCrossRef Flatt PR, Bailey CJ, Kwasowski P, Page T, Marks V (1984) Plasma immunoreactive gastric inhibitory polypeptide in obese hyperglycaemic (ob/ob) mice. J Endocrinol 101:249–256PubMedCrossRef
24.
Zurück zum Zitat Vilsbøll T, Krarup T, Sonne J et al (2003) Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab 88:2706–2713PubMedCrossRef Vilsbøll T, Krarup T, Sonne J et al (2003) Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab 88:2706–2713PubMedCrossRef
25.
Zurück zum Zitat McClean PL, Irwin N, Cassidy RS, Holst JJ, Gault VA, Flatt PR (2007) GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet. Am J Physiol Endocrinol Metab 293:E1746–E1755PubMedCrossRef McClean PL, Irwin N, Cassidy RS, Holst JJ, Gault VA, Flatt PR (2007) GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet. Am J Physiol Endocrinol Metab 293:E1746–E1755PubMedCrossRef
26.
Zurück zum Zitat Gault VA, Irwin N, Green BD et al (2005) Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes. Diabetes 54:2436–2446PubMedCrossRef Gault VA, Irwin N, Green BD et al (2005) Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes. Diabetes 54:2436–2446PubMedCrossRef
27.
Zurück zum Zitat Damholt AB, Kofod H, Buchan AM (1999) Immunocytochemical evidence for a paracrine interaction between GIP and GLP-1-producing cells in canine small intestine. Cell Tissue Res 298:287–293PubMedCrossRef Damholt AB, Kofod H, Buchan AM (1999) Immunocytochemical evidence for a paracrine interaction between GIP and GLP-1-producing cells in canine small intestine. Cell Tissue Res 298:287–293PubMedCrossRef
28.
Zurück zum Zitat McClean PL, Irwin N, Hunter K, Gault VA, Flatt PR (2008) (Pro(3))GIP[mPEG]: novel, long-acting, mPEGylated antagonist of gastric inhibitory polypeptide for obesity-diabetes (diabesity) therapy. Br J Pharmacol 155:690–701PubMedCrossRef McClean PL, Irwin N, Hunter K, Gault VA, Flatt PR (2008) (Pro(3))GIP[mPEG]: novel, long-acting, mPEGylated antagonist of gastric inhibitory polypeptide for obesity-diabetes (diabesity) therapy. Br J Pharmacol 155:690–701PubMedCrossRef
29.
Zurück zum Zitat Rubino F (2008) Is type 2 diabetes an operable intestinal disease? A provocative yet reasonable hypothesis. Diabetes Care 31:S290–S296PubMedCrossRef Rubino F (2008) Is type 2 diabetes an operable intestinal disease? A provocative yet reasonable hypothesis. Diabetes Care 31:S290–S296PubMedCrossRef
Metadaten
Titel
Circadian rhythms of GIP and GLP1 in glucose-tolerant and in type 2 diabetic patients after biliopancreatic diversion
verfasst von
G. Mingrone
G. Nolfe
G. Castagneto Gissey
A. Iaconelli
L. Leccesi
C. Guidone
G. Nanni
J. J. Holst
Publikationsdatum
01.05.2009
Verlag
Springer-Verlag
Erschienen in
Diabetologia / Ausgabe 5/2009
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-009-1288-9

Weitere Artikel der Ausgabe 5/2009

Diabetologia 5/2009 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.